Agios Pharmaceuticals IncNASDAQ:AGIO
- LAST PRICE46.9000
- TODAY'S CHANGE (%)1.1400 (2.4913%)
- Bid / Lots46.8500/ 4
- Ask / Lots46.9500/ 2
- Open / Previous Close45.8000 / 45.7600
- Day Range
- 52 Week Range
- Volume186,298
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AGIO |
|---|---|---|
| 09:32 ET | 2054 | 45.8 |
| 09:36 ET | 200 | 45.47 |
| 09:38 ET | 1034 | 45.325 |
| 09:41 ET | 908 | 46.09 |
| 09:45 ET | 1000 | 45.755 |
| 09:48 ET | 100 | 46.06 |
| 09:50 ET | 3334 | 46.2 |
| 09:52 ET | 17266 | 46.43 |
| 09:54 ET | 1000 | 46.51 |
| 09:56 ET | 400 | 46.275 |
| 09:57 ET | 830 | 46.245 |
| 09:59 ET | 906 | 46.155 |
| 10:01 ET | 635 | 46.035 |
| 10:03 ET | 1200 | 46.15 |
| 10:08 ET | 662 | 46.025 |
| 10:10 ET | 100 | 46.025 |
| 10:12 ET | 826 | 45.98 |
| 10:14 ET | 800 | 46.04 |
| 10:15 ET | 338 | 45.985 |
| 10:17 ET | 1300 | 45.92 |
| 10:19 ET | 1822 | 45.64 |
| 10:21 ET | 725 | 45.72 |
| 10:24 ET | 215 | 45.555 |
| 10:26 ET | 105 | 45.54 |
| 10:28 ET | 700 | 45.67 |
| 10:30 ET | 600 | 45.5 |
| 10:32 ET | 300 | 45.475 |
| 10:33 ET | 4681 | 45.185 |
| 10:35 ET | 1763 | 45.245 |
| 10:37 ET | 5458 | 45.13 |
| 10:39 ET | 400 | 45.08 |
| 10:42 ET | 1145 | 44.87 |
| 10:44 ET | 100 | 45.015 |
| 10:46 ET | 676 | 44.98 |
| 10:48 ET | 2134 | 45.18 |
| 10:50 ET | 300 | 45.19 |
| 10:51 ET | 500 | 45.32 |
| 10:55 ET | 100 | 45.355 |
| 10:57 ET | 100 | 45.365 |
| 11:02 ET | 1000 | 45.27 |
| 11:04 ET | 400 | 45.18 |
| 11:06 ET | 100 | 45.195 |
| 11:08 ET | 200 | 45.205 |
| 11:09 ET | 987 | 45.31 |
| 11:11 ET | 300 | 45.34 |
| 11:13 ET | 339 | 45.36 |
| 11:18 ET | 200 | 45.46 |
| 11:20 ET | 400 | 45.66 |
| 11:22 ET | 200 | 45.69 |
| 11:24 ET | 500 | 45.65 |
| 11:26 ET | 500 | 45.59 |
| 11:27 ET | 900 | 45.78 |
| 11:29 ET | 800 | 45.74 |
| 11:31 ET | 200 | 45.795 |
| 11:33 ET | 200 | 45.92 |
| 11:36 ET | 200 | 45.915 |
| 11:38 ET | 200 | 45.905 |
| 11:40 ET | 3200 | 46 |
| 11:42 ET | 203 | 45.945 |
| 11:45 ET | 200 | 45.935 |
| 11:47 ET | 1300 | 46.03 |
| 11:49 ET | 200 | 45.99 |
| 11:51 ET | 500 | 46.05 |
| 11:54 ET | 100 | 46.095 |
| 11:56 ET | 233 | 46.15 |
| 11:58 ET | 200 | 46.235 |
| 12:00 ET | 3100 | 46.17 |
| 12:02 ET | 1122 | 46.27 |
| 12:03 ET | 300 | 46.23 |
| 12:05 ET | 100 | 46.225 |
| 12:07 ET | 100 | 46.255 |
| 12:09 ET | 1000 | 46.21 |
| 12:12 ET | 1786 | 46.25 |
| 12:16 ET | 2900 | 46.25 |
| 12:18 ET | 600 | 46.15 |
| 12:20 ET | 400 | 46.24 |
| 12:23 ET | 2827 | 46.31 |
| 12:25 ET | 1107 | 46.21 |
| 12:27 ET | 525 | 46.225 |
| 12:30 ET | 100 | 46.225 |
| 12:32 ET | 600 | 46.27 |
| 12:34 ET | 700 | 46.37 |
| 12:36 ET | 100 | 46.32 |
| 12:41 ET | 600 | 46.335 |
| 12:43 ET | 1089 | 46.276 |
| 12:45 ET | 2055 | 46.35 |
| 12:48 ET | 100 | 46.37 |
| 12:50 ET | 200 | 46.335 |
| 12:52 ET | 600 | 46.29 |
| 12:54 ET | 200 | 46.32 |
| 12:56 ET | 600 | 46.36 |
| 12:59 ET | 200 | 46.27 |
| 01:01 ET | 335 | 46.25 |
| 01:06 ET | 200 | 46.315 |
| 01:08 ET | 1000 | 46.48 |
| 01:12 ET | 454 | 46.4942 |
| 01:14 ET | 100 | 46.51 |
| 01:15 ET | 200 | 46.515 |
| 01:17 ET | 900 | 46.58 |
| 01:19 ET | 800 | 46.51 |
| 01:26 ET | 372 | 46.63 |
| 01:30 ET | 100 | 46.615 |
| 01:32 ET | 600 | 46.57 |
| 01:33 ET | 301 | 46.56 |
| 01:35 ET | 1779 | 46.66 |
| 01:37 ET | 100 | 46.67 |
| 01:42 ET | 1200 | 46.54 |
| 01:44 ET | 200 | 46.56 |
| 01:50 ET | 400 | 46.7682 |
| 01:51 ET | 100 | 46.72 |
| 01:53 ET | 117 | 46.65 |
| 01:55 ET | 955 | 46.8 |
| 01:57 ET | 100 | 46.755 |
| 02:02 ET | 100 | 46.75 |
| 02:04 ET | 200 | 46.76 |
| 02:06 ET | 300 | 46.765 |
| 02:08 ET | 1779 | 46.755 |
| 02:11 ET | 100 | 46.76 |
| 02:13 ET | 332 | 46.845 |
| 02:15 ET | 200 | 46.84 |
| 02:18 ET | 200 | 46.84 |
| 02:20 ET | 800 | 46.8 |
| 02:22 ET | 300 | 46.8 |
| 02:24 ET | 200 | 46.805 |
| 02:29 ET | 500 | 46.835 |
| 02:31 ET | 1300 | 46.782 |
| 02:33 ET | 1100 | 46.9 |
| 02:36 ET | 450 | 46.9 |
Sep 19, 2024
DJ Agios Pharmaceuticals Price Target Maintained With a $55.00/Share by RBC Capital, from 9:18AM ET on Thursday Sep 19, 2024 by Dow Jones
9:18AM ET on Thursday Sep 19, 2024 by Dow Jones
Sep 11, 2024
DJ Agios Gets FDA Orphan Designation for Tebapivat in Myelodysplastic Syndromes, from 7:28AM ET on Wednesday Sep 11, 2024 by Dow Jones
7:28AM ET on Wednesday Sep 11, 2024 by Dow JonesAgios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS), from 7:00AM ET on Wednesday Sep 11, 2024 by Dow Jones
7:00AM ET on Wednesday Sep 11, 2024 by Dow Jones
Sep 5, 2024
Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024, from 7:00AM ET on Thursday Sep 05, 2024 by Dow Jones
7:00AM ET on Thursday Sep 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Agios Pharmaceuticals Inc | 2.6B | -7.2x | --- |
Janux Therapeutics Inc | 2.6B | -54.5x | --- |
Celldex Therapeutics Inc | 2.7B | -15.1x | --- |
Geron Corp | 2.6B | -12.6x | --- |
CG Oncology Inc | 2.6B | -32.0x | --- |
IDEAYA Biosciences Inc | 2.8B | -14.6x | --- |
Company Information
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.
Contact Information
- Headquarters
- 88 Sidney StreetCAMBRIDGE, MA, United States 02139
- Phone
- 617-649-8600
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Jacqualyn Fouse
- Chief Executive Officer, Director
- Brian Goff
- Chief Financial Officer
- Cecilia Jones
- Chief Legal Officer
- James Burns
- Chief Medical Officer, Head - Research and Development
- Sarah Gheuens
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.6B |
|---|---|
Revenue (TTM) | $31.3M |
Shares Outstanding | 56.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.75 |
EPS | $-6.49 |
Book Value | $14.50 |
P/E Ratio | -7.2x |
Price/Sales (TTM) | 83.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,293.88% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
